Our Pipelines

In this section you will find current statistics on our products. Our drug for the treatment of brain and liver cancer has received (*) Orphan Drug Designation from the EMA.

SI-053

(brain tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

SA-033

(liver tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

SA-083

(lung tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

GenNexis-DB

GenNexis-DB is an advanced AI-driven platform designed to revolutionize drug discovery by generating allosteric activators, blockers, and stabilizers. The platform addresses one of the most significant challenges in drug design: the precise identification and creation of allosteric modulators that can finely tune protein function. Traditional drug discovery methods are often time-consuming and costly, particularly in the development of allosteric compounds. GenNexis-DB integrates AI technologies to accelerate this process, incorporating synthetic accessibility and “druglikeness” into the design, ensuring that generated compounds are not only promising but also feasible for synthesis. By eliminating the need for extensive datasets, GenNexis-DB enables rapid generation and optimization of allosteric modulators, focusing on their potential therapeutic impact.